Novavax Inc (NVAX) 6.77 $NVAX Uptrend Call Working As

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Novavax Inc (NVAX) 6.77 $NVAX

Uptrend Call Working As Novavax Stock Rises 30.8% (NVAX)
Comtex SmarTrend(R) - Fri Aug 26, 1:28PM CDT
SmarTrend identified an Uptrend for Novavax (NASDAQ:NVAX) on May 24th, 2016 at $5.45. In approximately 3 months, Novavax has returned 30.76% as of today's recent price of $7.12.
NVAX: 6.77 (-0.05)

Novavax Up 26.5% Since SmarTrend Uptrend Call (NVAX)
Comtex SmarTrend(R) - Thu Aug 11, 1:28PM CDT
SmarTrend identified an Uptrend for Novavax (NASDAQ:NVAX) on May 24th, 2016 at $5.45. In approximately 3 months, Novavax has returned 26.54% as of today's recent price of $6.89.
NVAX: 6.77 (-0.05)

Novavax Set to Possibly Rebound After Yesterday's Selloff of 9.84%
Comtex SmarTrend(R) - Wed Aug 10, 2:01PM CDT
Novavax (NASDAQ:NVAX) traded in a range yesterday that spanned from a low of $6.81 to a high of $7.37. Yesterday, the shares fell 9.8%, which took the trading range below the 3-day low of $7.46 on volume of 7.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
NVAX: 6.77 (-0.05)

Novavax Reports Second Quarter 2016 Financial Results
GlobeNewswire - Tue Aug 09, 3:08PM CDT
Novavax, Inc., (Nasdaq:NVAX) today announced its financial results for the second quarter and six months ended June 30, 2016.
NVAX: 6.77 (-0.05)

Novavax Has Returned 39.8% Since SmarTrend Recommendation (NVAX)
Comtex SmarTrend(R) - Thu Aug 04, 12:51AM CDT
SmarTrend identified an Uptrend for Novavax (NASDAQ:NVAX) on May 24th, 2016 at $5.45. In approximately 2 months, Novavax has returned 39.76% as of today's recent price of $7.61.
NVAX: 6.77 (-0.05)

Novavax to Host Conference Call to Discuss Second Quarter Financial Results on August 9, 2016
GlobeNewswire - Tue Aug 02, 3:07PM CDT
Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced it will report its second quarter 2016 financial and operating results after the close of U.S. financial markets on Tuesday, August 9, 2016.
NVAX: 6.77 (-0.05)

35.5% Return Seen to Date on SmarTrend Novavax Call (NVAX)
Comtex SmarTrend(R) - Wed Jul 27, 1:10PM CDT
SmarTrend identified an Uptrend for Novavax (NASDAQ:NVAX) on May 24th, 2016 at $5.45. In approximately 2 months, Novavax has returned 35.49% as of today's recent price of $7.38.
NVAX: 6.77 (-0.05)

Interesting NVAX Put And Call Options For August 19th
DividendChannel.com - Tue Jun 21, 9:38AM CDT
Investors in Novavax, Inc. saw new options begin trading this week, for the August 19th expiration.
NVAX: 6.77 (-0.05)

Novavax Recognized by Washington Post as Top Workplace
GlobeNewswire - Fri Jun 17, 7:30AM CDT
Novavax, Inc. (Nasdaq:NVAX), today announced that, for the third consecutive year, it has been recognized as a Top Workplace for 2016.
NVAX: 6.77 (-0.05)

Novavax Has Returned 24.3% Since SmarTrend Recommendation (NVAX)
Comtex SmarTrend(R) - Fri Jun 17, 1:08AM CDT
SmarTrend identified an Uptrend for Novavax (NASDAQ:NVAX) on May 24th, 2016 at $5.45. In approximately 3 weeks, Novavax has returned 24.33% as of today's recent price of $6.77.
NVAX: 6.77 (-0.05)

Novavax Rises 2.81% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Wed Jun 15, 3:05PM CDT
Novavax (NASDAQ:NVAX) traded in a range yesterday that spanned from a low of $6.59 to a high of $6.90. Yesterday, the shares gained 2.8%, which took the trading range above the 3-day high of $6.64 on volume of 2.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
NVAX: 6.77 (-0.05)

23.4% Return Seen to Date on SmarTrend Novavax Call (NVAX)
Comtex SmarTrend(R) - Thu Jun 09, 1:55PM CDT
SmarTrend identified an Uptrend for Novavax (NASDAQ:NVAX) on May 24th, 2016 at $5.45. In approximately 2 weeks, Novavax has returned 23.42% as of today's recent price of $6.72.
NVAX: 6.77 (-0.05)

Novavax Announces New Seasonal Combination Respiratory Vaccine Program
Globe Newswire - Thu Jun 02, 3:11PM CDT
- Seasonal influenza nanoparticle approach replaces VLP program
NVAX: 6.77 (-0.05)

Novavax Rises 6.66% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Tue May 31, 5:08PM CDT
Novavax (NASDAQ:NVAX) traded in a range yesterday that spanned from a low of $5.93 to a high of $6.29. Yesterday, the shares gained 6.7%, which took the trading range above the 3-day high of $6.06 on volume of 4.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
NVAX: 6.77 (-0.05)

U.S. FDA Grants Fast Track Designation to Novavax' RSV F Vaccine for Older Adults
Globe Newswire - Wed May 25, 7:01AM CDT
GAITHERSBURG, Md., May 25, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to Novavax' RSV F-Protein nanoparticle vaccine candidate (RSV F Vaccine) for the protection of older adults (60 years of age and older).
NVAX: 6.77 (-0.05)

After Yesterday's Rally of 2.48% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Mon May 23, 4:22PM CDT
Novavax (NASDAQ:NVAX) traded in a range yesterday that spanned from a low of $5.26 to a high of $5.47. Yesterday, the shares gained 2.5%, which took the trading range above the 3-day high of $5.31 on volume of 2.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
NVAX: 6.77 (-0.05)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

AnaptysBio's Upcoming Investor Conference Schedule Explained

Updated Category News Views 181

Overview of AnaptysBio's Investor Engagement AnaptysBio, Inc. (NASDAQ: ANAB), based in San Diego, is recognized in the biotechnology sector for its commitment to advancing immunology therapies. This clinical-stage company focuses on tackling autoimmune disorders and inflammatory diseases through innovative therapeutics. Recently, AnaptysBio's president and CEO, Daniel...

Continue Reading
Truist Q2 2026 Earnings: Key Highlights and Insights

Updated Category News Views 12

Truist's Big Second Quarter Reveal Boy, isn't it just the way, you blink, and another quarterly earnings season rolls around. Today, it's Truist Financial Corporation (NYSE: TFC) spilling the beans on their second quarter of 2026. If you have even a passing interest in commercial banking, there's fresh data to chew over. But, let's not beat around the bush—it ain't just...

Continue Reading
RadCred Revolutionizes Payday Loans for Borrowers with Bad Credit

Updated Category News Views 203

RadCred's Innovative Approach to Payday Loans RadCred has made waves in the financial industry with the launch of its AI-driven payday loan service, specifically catering to individuals grappling with bad credit. This groundbreaking platform presents a solution that addresses the financial dilemmas many Americans face when traditional lending avenues are not an option....

Continue Reading
Stingray Karaoke Revolutionizes NIO Vehicles for European Drivers

Updated Category News Views 185

Exciting New Karaoke Feature for NIO Vehicles Stingray, well-known in the music and media industry, is excited to announce its latest partnership with NIO, a leader in smart electric vehicle technology. The launch of Stingray Karaoke in NIO vehicles across Europe is set to change the driving experience into a lively and interactive musical adventure. This feature not only...

Continue Reading
Urgent Literacy Data from Amplify Highlights Education Gaps

Updated Category News Views 197

Salient Takeaways from Amplify's Latest Literacy Findings The latest literacy data from Amplify paints a sobering picture of our K–2 readers. Only 57% of these young students are on track to meet fundamental reading benchmarks at this point in the academic year. Let that sink in for a second. What does it say about our efforts as a society? The Effects of the Pandemic...

Continue Reading